British Journal of Medical & Surgical Urology
Volume 1, Issue 3 , Pages 107-119 , November 2008

Prostate cancer staging tables—A predictive model for the UK

  • Simon R.J. Bott

      Affiliations

    • Frimley Park Hospital, Portsmouth Road, Frimley, Surrey. GU16 7UJ, UK
    • Corresponding Author InformationCorresponding author.
    • ,
  • Mark Emberton

      Affiliations

    • University College Hospital, 235 Euston Road, London, NW1 2BU, UK
    • ,
  • Matthew R. Sydes

      Affiliations

    • MRC Clinical Trials Unit (Cancer Group), London, NW1 2DA, UK
    • ,
  • the surgical and pathological contributors

Received 7 July 2008 ,Accepted 7 August 2008.

References 

  1. Specht MC, Kattan MW, Gonen M, Fey J, Van Zee KJ. Predicting nonsentinel node status after positive sentinel lymph biopsy for breast cancer: clinicians versus nomogram. Ann Surg Oncol. 2005;12:6549
  2. Steuber T, Graefen M, Haese A, Erbersdobler A, Chun FK, Schlom T, et al. Validation of a nomogram for prediction of side specific extracapsular extension at radical prostatectomy. J Urol. 2006;175(3 Pt 1):939–944
  3. Ross PL, Gerigk C, Gonen M, Yossepowitch O, Cagiannos I, Sogani PC, et al. Comparisons of nomograms and urologists’ predictions in prostate cancer. Semin Urol Oncol. 2002;20(2):82–88
  4. Stapleton AM, Pinnock CB. Nomograms for prostate cancer—is their use evidence-based?. Nat Clin Pract Urol. 2005;2(10):462–463
  5. Partin AW, Mangold LA, Lamm DM, Walsh PC, Epstein JI, Pearson JD. Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium. Urology. 2001;58(6):843–848
  6. Stephenson AJ, Scardino PT, Eastham JA, Bianco FJ, Dotan ZA, Fearn PA, et al. Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Natl Cancer Inst. 2006;98(10):715–717
  7. D’Amico AV, Whittington R, Malkowicz SB, Wu YH, Chen M, Art M, et al. Combination of the preoperative PSA level, biopsy Gleason score, percentage of positive biopsies, and MRI T-stage to predict early PSA failure in men with clinically localized prostate cancer. Urology. 2000;55(4):572–577
  8. Greene KL, Meng MV, Elkin EP, Cooperberg MR, Pasta DJ, Kattan MW, et al. Validation of the Kattan preoperative nomogram for prostate cancer recurrence using a community based cohort: results from cancer of the prostate strategic urological research endeavor (capsure). J Urol. 2004;171(6 Pt 1):2255–2259
  9. Mitchell JA, Cooperberg MR, Elkin EP, Lubeck DP, Mehta SS, Kane CJ, et al. Ability of 2 pretreatment risk assessment methods to predict prostate cancer recurrence after radical prostatectomy: data from CaPSURE. J Urol. 2005;173(4):1126–1131
  10. Briganti A, Shariat SF, Chun FK, Hutterer GC, Roehrborn CG, Gallina A, et al. Differences in the rate of lymph node invasion in men with clinically localized prostate cancer might be related to the continent of origin. BJU Int. 2007;100(3):528–532
  11. Quinn M, Babb P. Patterns and trends in prostate cancer incidence, survival, prevalence and mortality. Part I. international comparisons. BJU Int. 2002;90(2):162–173
  12. Quinn M, Babb P. Patterns and trends in prostate cancer incidence, survival, prevalence and mortality. Part II. Individual countries. BJU Int. 2002;90(2):174–184
  13. Bott SR, Freeman AA, Stenning S, Cohen J, Parkinson MC. Radical prostatectomy: pathology findings in 1001 cases compared with other major series and over time. BJU Int. 2005;95(1):34–39
  14. Han M, Partin AW, Piantadosi S, Epstein JI, Walsh PC. Era specific biochemical recurrence-free survival following radical prostatectomy for clinically localized prostate cancer. J Urol. 2001;166(2):416–419
  15. Babaian RJ, Troncoso P, Bhadkamkar VA, Johnston DA. Analysis of clinicopathologic factors predicting outcome after radical prostatectomy. Cancer. 2001;91(8):1414–1422
  16. Quinn DI, Henshall SM, Haynes AM, Brenner PC, Kooner R, Golovsky D, et al. Prognostic significance of pathologic features in localized prostate cancer treated with radical prostatectomy: implications for staging systems and predictive models. J Clin Oncol. 2001;19(16):3692–3705
  17. Lotan Y, Shariat SF, Khoddami SM, Saboorian H, Koeneman KS, Cadeddu JA, et al. The percent of biopsy cores positive for cancer is a predictor of advanced pathological stage and poor clinical outcomes in patients treated with radical prostatectomy. J Urol. 2004;171(6 Pt 1):2209–2214
  18. Sebo TJ, Bock BJ, Cheville JC, Lohse C, Wollan P, Zincke H. The percent of cores positive for cancer in prostate needle biopsy specimens is strongly predictive of tumor stage and volume at radical prostatectomy. J Urol. 2000;163(1):174–178
  19. Freedland SJ, Csathy GS, Dorey F, Aronson WJ. Percent prostate needle biopsy tissue with cancer is more predictive of biochemical failure or adverse pathology after radical prostatectomy than prostate specific antigen or Gleason score. J Urol. 2002;167(2 Pt 1):516–520
  20. Stamey TA, Caldwell M, McNeal JE, Nolley R, Hemenez M, Downs J. The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years?. J Urol. 2004;172(4 Pt 1):1297–1301
  21. Stapleton AM, Stahl J, Pinnock C, Humphrey K, Kopsaftis T. Patient profile predicts findings from radical prostatectomy series. BJU Int. 2005;95(Suppl. 1):16
  22. Freedland SJ, Hotaling JM, Fitzsimons NJ, Presti JC, Kane CJ, Terris MK, et al. PSA in the new millennium: a powerful predictor of prostate cancer prognosis and radical prostatectomy outcomes—results from the SEARCH database. Eur Urol. 2007;
  23. Chun FK, Briganti A, Gallina A, Hutterer GC, Shariat SF, Antebie E, et al. Prostate-specific antigen improves the ability of clinical stage and biopsy Gleason sum to predict the pathologic stage at radical prostatectomy in the new millennium. Eur Urol. 2007;52(4):1067–1075
  24. Jewett HJ, Bridge RW, Gray GF, Shelley WM. The palpable nodule of prostatic cancer. Results 15 years after radical excision. JAMA. 1968;203(6):403–406
  25. Catalona WJ, Smith DS. Cancer recurrence and survival rates after anatomic radical retropubic prostatectomy for prostate cancer: intermediate-term results. J Urol. 1998;160(6 Pt 2):2428–2434
  26. Hull GW, Rabbani F, Abbas F, Wheeler TM, Kattan MW, Scardino PT. Cancer control with radical prostatectomy alone in 1,000 consecutive patients. J Urol. 2002;167(2 Pt 1):528–534
  27. Salomon L, Levrel O, Anastasiadis AG, Irani J, De La TA, Saint F, et al. Prognostic significance of tumor volume after radical prostatectomy: a multivariate analysis of pathological prognostic factors. Eur Urol. 2003;43(1):39–44
  28. Carini M, Masieri L, Minervini A, Lapini A, Serni S. Oncological and functional results of antegrade radical retropubic prostatectomy for the treatment of clinically localised prostate cancer. Eur Urol. 2007;
  29. Rodriguez-Covarrubias F, Larre S, Dahan M, De La TA, Allory Y, Yiou R, et al. Invasion of bladder neck after radical prostatectomy: one definition for different outcomes. Prostate Cancer Prostatic Dis. 2007;
  30. Bott SR. Management of recurrent disease after radical prostatectomy. Prostate Cancer Prostatic Dis. 2004;7(3):211–216
  31. Moul JW. Prostate specific antigen only progression of prostate cancer. J Urol. 2000;163(6):1632–1642
  32. Polascik TJ, Oesterling JE, Partin AW. Prostate specific antigen: a decade of discovery—what we have learned and where we are going. J Urol. 1999;162(2):293–306
  33. Amling CL, Bergstralh EJ, Blute ML, Slezak JM, Zincke H. Defining prostate specific antigen progression after radical prostatectomy: what is the most appropriate cut point?. J Urol. 2001;165(4):1146–1151
  34. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA. 1999;281(17):1591–1597
  35. D’Amico AV, Moul JW, Carroll PR, Sun L, Lubeck D, Chen MH. Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Natl Cancer Inst. 2003;95(18):1376–1383
  36. Gretzer MB, Trock BJ, Han M, Walsh PC. A critical analysis of the interpretation of biochemical failure in surgically treated patients using the American Society for Therapeutic Radiation and Oncology criteria. J Urol. 2002;168(4 Pt 1):1419–1422
  37. Kattan MW. Expert systems in medicine. In:  Smelser NJ,  Baltes PB editor. International encyclopedia of the social and behavioral sciences. Oxford: Pergamon; 2001;p. 5135–5139
  38. Ross PL, Scardino PT, Kattan MW. A catalog of prostate cancer nomograms. J Urol. 2001;165(5):1562–1568
  39. Makarov DV, Trock BJ, Humphreys EB, Mangold LA, Walsh PC, Epstein JI, et al. Updated nomogram to predict pathologic stage of prostate cancer given prostate-specific antigen level, clinical stage, and biopsy Gleason score (Partin tables) based on cases from 2000 to 2005. Urology. 2007;69(6):1095–1101
  40. National Institute for Health and Clinical Excellence. Prostate cancer: diagnosis and treatment. CG58 Prostate cancer: Full guidance 2008.
  41. Graefen M, Karakiewicz PI, Cagiannos I, Quinn DI, Henshall SM, Grygiel JJ, et al. International validation of a preoperative nomogram for prostate cancer recurrence after radical prostatectomy. J Clin Oncol. 2002;20(15):3206–3212

PII: S1875-9742(08)00069-4

doi: 10.1016/j.bjmsu.2008.08.002

British Journal of Medical & Surgical Urology
Volume 1, Issue 3 , Pages 107-119 , November 2008

Article Tools